Literature DB >> 18159509

The management of chronic viral hepatitis: A Canadian consensus conference 2004.

Morris Sherman1, Vincent Bain, Jean-Pierre Villeneuve, Robert P Myers, Curtis Cooper, Steven Martin, Catherine Lowe.   

Abstract

Several government and nongovernment organizations held a consensus conference on the management of acute and chronic viral hepatitis to update previous management recommendations. The conference became necessary because of the introduction of new forms of therapy for both hepatitis B and hepatitis C. The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon. The treatment of hepatitis B in several special situations was also discussed. There were also recommendations on the investigation and treatment of chronic hepatitis C and hepatitis C-HIV coinfection. In addition, the document makes some recommendations about the provision of services by provincial governments to facilitate the delivery of care to patients with hepatitis virus infection. The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care.

Entities:  

Keywords:  Adefovir; Chronic viral hepatitis; Interferon; Lamivudine

Year:  2004        PMID: 18159509      PMCID: PMC2094989          DOI: 10.1155/2004/326964

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  137 in total

Review 1.  Challenges in therapy of chronic hepatitis B.

Authors:  Jay H Hoofnagle
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

3.  Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.

Authors:  B J McMahon; P Holck; L Bulkow; M Snowball
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

4.  Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.

Authors:  P Marcellin; N Boyer; A Gervais; M Martinot; M Pouteau; C Castelnau; A Kilani; J Areias; A Auperin; J P Benhamou; C Degott; S Erlinger
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

5.  Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.

Authors:  L C Da Silva; J R Pinho; R Sitnik; L E Da Fonseca; F J Carrilho
Journal:  J Gastroenterol       Date:  2001-07       Impact factor: 7.527

6.  Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.

Authors:  P Mathurin; J Moussalli; J F Cadranel; V Thibault; F Charlotte; P Dumouchel; A Cazier; J M Huraux; B Devergie; M Vidaud; P Opolon; T Poynard
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

7.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

8.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

9.  Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Authors:  Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

10.  Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report.

Authors:  A R Zanetti; P Dentico; C Del Vecchio Blanco; E Sagnelli; E Villa; P Ferroni; F Bergamini
Journal:  J Med Virol       Date:  1986-04       Impact factor: 2.327

View more
  8 in total

1.  Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users.

Authors:  Joseph Cox; Carole Morissette; Prithwish De; Claude Tremblay; Robert Allard; Lisa Graves; Randolph Stephenson; Elise Roy
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

Review 2.  [Consensus methods: review of original methods and their main alternatives used in public health].

Authors:  F Bourrée; P Michel; L R Salmi
Journal:  Rev Epidemiol Sante Publique       Date:  2008-11-13       Impact factor: 1.019

3.  A mathematical model to study the effect of hepatitis B virus vaccine and antivirus treatment among the Canadian Inuit population.

Authors:  C O'Leary; Z Hong; F Zhang; M Dawood; G Smart; K Kaita; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-12       Impact factor: 3.267

4.  Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations.

Authors:  Jane A Buxton; Jin Hee Kim
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-03       Impact factor: 2.471

5.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

6.  Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials.

Authors:  Kelly De Kaita; Stephen Wong; Eberhard Renner; Gerald Y Minuk
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

7.  Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Authors:  Cecilia T Costiniuk; Edward Mills; Curtis L Cooper
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

8.  Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Roberto J Carvalho-Filho; Olav Dalgard
Journal:  Pharmgenomics Pers Med       Date:  2010-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.